Medicenna Therapeutics Corp represents values of innovation, dedication, and commitment to improving patient outcomes in the biopharmaceutical industry. With a strong corporate philosophy centered around developing novel targeted therapies, Medicenna aims to address unmet medical needs and transform the lives of individuals affected by severe diseases. The company is dedicated to advancing its pipeline, leveraging its unique Empowered Cytokines™ protein therapeutics platform, and collaborating with healthcare professionals, researchers, and patient advocacy groups to drive meaningful advancements in cancer treatment. Medicenna Therapeutics Corp strives to make a significant impact on the healthcare landscape through its innovative approaches and patient-centric focus.

Medicenna Therapeutics Corp primarily operates in Canada and the United States.

Medicenna Therapeutics Corp has achieved several significant milestones. The company successfully completed Phase 2b clinical trials of its lead drug candidate MDNA55, showcasing promising results in treating recurrent glioblastoma, a highly aggressive brain cancer. Medicenna also received Fast Track designation from the U.S. FDA for MDNA55, validating its potential as a breakthrough therapy. Furthermore, the company signed a strategic partnership and licensing agreement with a major global pharmaceutical company to advance MDNA55's development and commercialization. These milestones highlight Medicenna Therapeutics Corp's dedication to developing innovative and effective treatments for patients in need.

Founded in 2011, Medicenna Therapeutics Corp is a clinical-stage biopharmaceutical company based in Canada. With a focus on developing precision medicines to treat oncology and auto-immune diseases, Medicenna Therapeutics utilizes cutting-edge technologies to create targeted immunotherapy products. The company's proprietary Medicenna Empowered Cytokines™ (MCs) platform has shown promising results in preclinical and clinical trials. By engineering cytokines to enhance their efficacy and minimize off-target side effects, Medicenna Therapeutics aims to revolutionize cancer treatment. With a dedicated team of scientists and collaborators, Medicenna Therapeutics Corp continues to strive for innovative therapies to address unmet medical needs.

Medicenna Therapeutics Corp faces competition from various companies in the market. Some of its main competitors include companies like AbbVie Inc., AstraZeneca PLC, Bristol Myers Squibb Company, and Merck & Co., Inc. These companies also operate in the field of biopharmaceuticals, oncology treatments, and immune-system drugs, making them competitors of Medicenna in terms of developing and commercializing innovative therapies. However, Medicenna Therapeutics Corp distinguishes itself through its unique approaches and advancements in immunotherapy, particularly in the areas of targeted delivery systems, cytokine therapies, and antibody-drug conjugates.

Medicenna Therapeutics Corp is primarily active in the healthcare and biotechnology industries.

The business model of Medicenna Therapeutics Corp focuses on developing and commercializing targeted immunotherapies for the treatment of cancer. The company's approach involves leveraging its proprietary drug discovery platform, called Empowered Cytokines™, to enhance the efficacy and safety of immunotherapies. By engineering cytokines, which are immune signaling molecules, Medicenna aims to create therapies that can selectively target and activate the patient's immune system to fight cancer without causing excessive toxicity. Through strategic collaborations and partnerships, Medicenna aims to further advance its innovative therapies and improve patient outcomes in the field of oncology.

KGV Medicenna Therapeutics iznosi −4,74.

Koeficijent cijene i prometa Medicenna Therapeutics iznosi 0.

AlleAktien Qualitätsscore za Medicenna Therapeutics je 1/10.

Prihod trenutno ne može biti izračunat za Medicenna Therapeutics.

Dobit očekivana Medicenna Therapeutics iznosi −19,40 mil. CAD.

Medicenna Therapeutics Corp is a Canadian biotech company specializing in the development of immunotherapies for the treatment of cancer and other serious diseases. The company uses a unique "DiffronCX" platform technology model to develop effective therapies tailored to the needs of patients. Medicenna focuses on developing cancer drugs that target aggressive tumors resistant to conventional therapies. The goal is to develop therapeutic solutions based on the genetic and molecular characteristics of tumor cells and the patient's immune system. The company believes that by using a science-based approach, strengthening the body's own immune defenses, and focusing on high-risk cancer types, it will be possible to develop effective treatments that improve patients' quality of life. Medicenna operates two production facilities. The main facility in Toronto covers 8,500 square meters and employs over 60 staff members. The second facility, located in Houston, TX, covers approximately 5,000 square meters and is used as a production unit for the company's Anti-IL-4Rα program. Both facilities cover all critical steps of the drug manufacturing chain, including production, purification, and formulation. Medicenna's flagship product is MDNA55, an immunotherapy for glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor in adults. Using Medicenna's DiffronCX technology, MDNA55 is a novel protein-toxin conjugate designed to selectively target CD-64 positive tumor cells. MDNA55 is currently in Phase II/III clinical development with positive results from Phase II showing effective reductions in tumor size and spread. The Phase II/III study is expected to begin in the US and Canada in 2019. In addition to MDNA55, Medicenna is currently developing an anti-IL-4Rα immunoglobulin gene therapy program for the treatment of asthma and other inflammatory lung diseases. This program is currently in preclinical development, but early animal studies have shown that it can significantly reduce lung inflammation in patients with asthma. Medicenna's business model is based on developing innovative tailored therapies that meet the needs and requirements of patients with serious diseases. By using cutting-edge technologies and highly skilled professionals, the company focuses on developing customized treatments that go beyond the limits of traditional medical care and provide patients with new hope. The company is committed to providing groundbreaking therapy options that have the potential to change patients' lives and advance medical progress.

Medicenna Therapeutics isplaćuje dividendu od 0 CAD raspoređenu preko isplata godišnje.

Dividenda za Medicenna Therapeutics trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Medicenna Therapeutics je CA58490H1073.

Oznaka burze tvrtke Medicenna Therapeutics je MDNA.TO.

U posljednjih 12 mjeseci Medicenna Therapeutics je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Medicenna Therapeutics će vjerojatno isplatiti dividendu u iznosu od 0 CAD.

Trenutni prinos dividende od Medicenna Therapeutics iznosi .

Medicenna Therapeutics isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Medicenna Therapeutics je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 CAD. To odgovara dividendnom prinosu od 0 %.

Medicenna Therapeutics se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od Medicenna Therapeutics od 02. 02. 2025. u iznosu od 0 CAD, trebali ste imati dionicu u portfelju prije Ex-dana 02. 02. 2025..

Posljednja isplata dividende izvršena je 02. 02. 2025..

U godini 2024 su od Medicenna Therapeutics 0 CAD isplaćene kao dividende.

Dividende od Medicenna Therapeutics isplaćuju se u CAD.